Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciclopirox. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | KDM4B | O94953 | 1/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.81 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.81 |
| ▸ | IDH1 | O75874 | 11/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciclopirox SCHEMBL514700 | 1.00 | KDM4E (1.00) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL1411724 | 1.00 | KDM4E (1.00) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL6264129 | 0.95 | KDM4E (0.90) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL28169345 | 0.95 | KDM4E (0.90) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL30969895 | 0.90 | NR1I2 (0.94) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL34424 | 0.90 | NR1I2 (1.00) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL1818483 | 0.90 | NR1I2 (1.00) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL4886428 | 0.85 | KDM4E (0.72) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL21571455 | 0.84 | NR1I2 (0.83) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL27927647 | 0.83 | KDM4E (0.71) | KDM4ELMNATP53CYP1A2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8396 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056882-A | Ciclopirox olamine nanoemulsion capable of effectively inhibiting fungi and application thereof | 江苏知原药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-121003222-B | Compound medicament and wheat stem basal rot comprehensive control method | 中国农业科学院植物保护研究所 | 2026-05-15 | — | — | CN | claimed |
| EP-4739300-A1 | MODULATORS OF IRON METABOLISM FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| CN-122011140-A | Method for rapidly identifying drug resistance of bakanae disease germ to fenugreek | 中国农业大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-3634361-B1 | HAIR CARE COMPOSITIONS CONTAINING EXTRACELLULAR METABOLITE PREPARATION FROM BACILLUS COAGULANS | SAMI SABINSA GROUP LTD (IN) | 2026-01-28 | — | — | EP | claimed |
| EP-4444272-B1 | A FORMULATION FOR AN EFFECTIVE ORAL ADMINISTRATION OF CICLOPIROX WITH NO ADVERSAL GASTEROINTESTINAL TOXICITY | ATLAS MOLECULAR PHARMA S L (ES) | 2025-11-26 | — | — | EP | claimed |
| US-12433856-B2 | Petrolatum-based compositions and methods of treatment for onychomycosis | GLOBAL HEALTH SOLUTIONS LLC | 2025-10-07 | — | — | US | claimed |
| CN-120060425-A | In-vitro cytotoxicity analysis method based on cisplatin combined ciclopirox olamine | 镇江市高等专科学校 | 2025-05-30 | — | — | CN | claimed |
| US-12310970-B2 | Compounds and methods for treating or preventing anterior segment ocular disorders and/or retinal degenerations | YALE UNIVERSITY (US) | 2025-05-27 | — | — | US | claimed |
| WO-1991002497-A1 | TOPICAL NIFEDIPINE FOR CUTANEOUS, OCULAR, MUCOSAL HYPERSENSITIVITY, INFLAMMATORY AND HYPERPROLIFERATIVE CONDITIONS | BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1991-03-07 | — | — | WO | claimed |
| WO-1990004828-A1 | SOFTWARE OPERATING ENVIRONMENT | A.C. NIELSEN COMPANY (US) | 1990-05-03 | — | — | WO | claimed |
| US-4891208-A | BILAYERS COMPRISING SALTS OF ORGANIC ACID DERIVATIVES OF STEROLS; ENTRAPMENT OF WATER SOLUBLE OR INSOLUBLE COMPOUNDS; DRUG DELIVERY | THE LIPOSOME COMPANY, INC. (US) | 1990-01-02 | — | — | US | claimed |
| US-4861580-A | Composition using salt form of organic acid derivative of alpha-tocopheral | THE LIPOSOME COMPANY, INC. (US) | 1989-08-29 | — | — | US | claimed |
| EP-0243446-A4 | ALPHA TOCOPHEROL-BASED VESICLES. | LIPOSOME CO INC (US) | 1988-06-23 | — | — | EP | claimed |
| EP-0222771-A4 | STEROIDAL LIPOSOMES. | LIPOSOME CORP (US) | 1988-06-08 | — | — | EP | claimed |
| EP-0243446-A1 | ALPHA TOCOPHEROL-BASED VESICLES. | LIPOSOME CO INC (US) | 1987-11-04 | — | — | EP | claimed |
| EP-0222771-A1 | STEROIDAL LIPOSOMES | THE LIPOSOME COMPANY, INC. (US) | 1987-05-27 | — | — | EP | claimed |
| WO-1987002219-A1 | ALPHA TOCOPHEROL-BASED VESICLES | THE LIPOSOME COMPANY, INC. (US) | 1987-04-23 | — | — | WO | claimed |
| WO-1986005977-A1 | STEROIDAL LIPOSOMES | THE LIPOSOME COMPANY, INC. (US) | 1986-10-23 | — | — | WO | claimed |